Do you want BuboFlash to help you learning these things? Or do you want to add or correct something? Click here to log in or create user.


  • Presentation
  • Question
  • Answer

Question
Kidney transplant recipients are predisposed to new-onset diabetes after transplantation (often referred to as NODAT). Medications that promote development of NODAT include glucocorticoids, [...], and the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus.
Answer
tacrolimus

Question
Kidney transplant recipients are predisposed to new-onset diabetes after transplantation (often referred to as NODAT). Medications that promote development of NODAT include glucocorticoids, [...], and the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus.
Answer
?

Question
Kidney transplant recipients are predisposed to new-onset diabetes after transplantation (often referred to as NODAT). Medications that promote development of NODAT include glucocorticoids, [...], and the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus.
Answer
tacrolimus
If you want to change selection, open original toplevel document below and click on "Move attachment"

Parent (intermediate) annotation

Open it
Kidney transplant recipients are predisposed to new-onset diabetes after transplantation (often referred to as NODAT). Medications that promote development of NODAT include glucocorticoids, tacrolimus, and the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus.

Original toplevel document (pdf)

owner: ELBOMBARDO - (no access) - MKSAP_17.pdf, p3418

Summary

statusnot learnedmeasured difficulty37% [default]last interval [days]               
repetition number in this series0memorised on               scheduled repetition               
scheduled repetition interval               last repetition or drill

Details

No repetitions

Discussion

Do you want to join discussion? Click here to log in or create user.